GlassScriptPhysician profile
Pranam Kokilakumar
NPI 1376938696
$9,114.65
in general payments reported to CMS, 2019-2025
34 companies · $1,356 in 2025
The $1,356 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26.00 · 2020: $300 · 2021: $2,315 · 2022: $1,748 · 2023: $1,682 · 2024: $1,688 · 2025: $1,356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,700 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,700.46 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,601.85 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,311.32 | 2021-2025 | |
| Lilly USA, LLC | $918.43 | 2020-2025 | Mounjaro, Zepbound, Kisunla |
| Abbott Laboratories | $758.15 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $683.96 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $287.86 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.50 | 2021-2025 | Jardiance |
| Amgen INC. | $281.02 | 2020-2024 | Repatha, Otezla, Evenity |
| Glaxosmithkline, LLC. | $249.73 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $206.64 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $191.71 | 2020-2025 | |
| Exact Sciences Corporation | $125.43 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.84 | 2021-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $108.49 | 2020-2025 | |
| Currax Pharmaceuticals LLC | $87.20 | 2021-2024 | Nexletol, Contrave, Nexlizet |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $83.41 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $82.64 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $82.56 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $75.77 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $67.79 | 2022 | |
| Horizon Therapeutics Plc | $66.01 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $64.97 | 2021 | |
| Idorsia Pharmaceuticals US INC | $64.13 | 2022-2023 | Quviviq |
| Genentech USA, INC. | $52.07 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $48.49 | 2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $46.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $38.13 | 2023-2024 | Belsomra, Gardasil 9, Gardasil |
| Amarin Pharma, INC. | $32.00 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $20.87 | 2025 | Keveyis |
| Verrica Pharmaceuticals INC. | $20.56 | 2024 | Ycanth |
| Boston Scientific Corporation | $19.24 | 2024 | Wavewriter Alpha Prime 16 |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2021 | |
| Endo Pharmaceuticals INC. | $12.00 | 2020 | |
| Dynavax Technologies Corporation | $10.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranam Kokilakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.